Cargando…
Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab
Rebound-associated vertebral fractures (RVFx) following denosumab discontinuation are typically multiple, are commonly associated with acute sharp pain, increase the risk of imminent fractures, and are pathogenetically different from common osteoporotic vertebral fractures (VFx). A clinically releva...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532339/ https://www.ncbi.nlm.nih.gov/pubmed/37762815 http://dx.doi.org/10.3390/jcm12185874 |
_version_ | 1785111936698941440 |
---|---|
author | Anastasilakis, Athanasios D. Makras, Polyzois Paccou, Julien Bisbinas, Ilias Polyzos, Stergios A. Papapoulos, Socrates E. |
author_facet | Anastasilakis, Athanasios D. Makras, Polyzois Paccou, Julien Bisbinas, Ilias Polyzos, Stergios A. Papapoulos, Socrates E. |
author_sort | Anastasilakis, Athanasios D. |
collection | PubMed |
description | Rebound-associated vertebral fractures (RVFx) following denosumab discontinuation are typically multiple, are commonly associated with acute sharp pain, increase the risk of imminent fractures, and are pathogenetically different from common osteoporotic vertebral fractures (VFx). A clinically relevant question is whether patients with RVFx should be managed differently from patients with osteoporotic VFx. To address this question, we performed a systematic search of the PubMed database, and we reviewed current evidence on the optimal management of patients with RVFx. For pain relief of patients with RVFx, potent analgesics, often opioids, are essential. Information on the effectiveness of braces in these patients is scarce. Vertebroplasty and kyphoplasty are strongly contraindicated as they confer a substantial risk for new VFx. Exercise may be helpful, but again evidence is lacking. In contrast to patients with osteoporotic VFx, in whom initial treatment with bone-forming agents is recommended, patients with RVFx should initiate treatment with potent antiresorptives. To summarize, patients who have sustained RVFx following denosumab discontinuation are at a very high risk for new fractures, especially VFx. The management of such patients requires a multidisciplinary approach that should not be restricted to pain relief and administration of antiosteoporotic medication, but should also include back protection, early mobilization, and appropriate exercise. |
format | Online Article Text |
id | pubmed-10532339 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105323392023-09-28 Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab Anastasilakis, Athanasios D. Makras, Polyzois Paccou, Julien Bisbinas, Ilias Polyzos, Stergios A. Papapoulos, Socrates E. J Clin Med Review Rebound-associated vertebral fractures (RVFx) following denosumab discontinuation are typically multiple, are commonly associated with acute sharp pain, increase the risk of imminent fractures, and are pathogenetically different from common osteoporotic vertebral fractures (VFx). A clinically relevant question is whether patients with RVFx should be managed differently from patients with osteoporotic VFx. To address this question, we performed a systematic search of the PubMed database, and we reviewed current evidence on the optimal management of patients with RVFx. For pain relief of patients with RVFx, potent analgesics, often opioids, are essential. Information on the effectiveness of braces in these patients is scarce. Vertebroplasty and kyphoplasty are strongly contraindicated as they confer a substantial risk for new VFx. Exercise may be helpful, but again evidence is lacking. In contrast to patients with osteoporotic VFx, in whom initial treatment with bone-forming agents is recommended, patients with RVFx should initiate treatment with potent antiresorptives. To summarize, patients who have sustained RVFx following denosumab discontinuation are at a very high risk for new fractures, especially VFx. The management of such patients requires a multidisciplinary approach that should not be restricted to pain relief and administration of antiosteoporotic medication, but should also include back protection, early mobilization, and appropriate exercise. MDPI 2023-09-10 /pmc/articles/PMC10532339/ /pubmed/37762815 http://dx.doi.org/10.3390/jcm12185874 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Anastasilakis, Athanasios D. Makras, Polyzois Paccou, Julien Bisbinas, Ilias Polyzos, Stergios A. Papapoulos, Socrates E. Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab |
title | Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab |
title_full | Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab |
title_fullStr | Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab |
title_full_unstemmed | Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab |
title_short | Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab |
title_sort | similarities and differences in the management of patients with osteoporotic vertebral fractures and those with rebound-associated vertebral fractures following discontinuation of denosumab |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532339/ https://www.ncbi.nlm.nih.gov/pubmed/37762815 http://dx.doi.org/10.3390/jcm12185874 |
work_keys_str_mv | AT anastasilakisathanasiosd similaritiesanddifferencesinthemanagementofpatientswithosteoporoticvertebralfracturesandthosewithreboundassociatedvertebralfracturesfollowingdiscontinuationofdenosumab AT makraspolyzois similaritiesanddifferencesinthemanagementofpatientswithosteoporoticvertebralfracturesandthosewithreboundassociatedvertebralfracturesfollowingdiscontinuationofdenosumab AT paccoujulien similaritiesanddifferencesinthemanagementofpatientswithosteoporoticvertebralfracturesandthosewithreboundassociatedvertebralfracturesfollowingdiscontinuationofdenosumab AT bisbinasilias similaritiesanddifferencesinthemanagementofpatientswithosteoporoticvertebralfracturesandthosewithreboundassociatedvertebralfracturesfollowingdiscontinuationofdenosumab AT polyzosstergiosa similaritiesanddifferencesinthemanagementofpatientswithosteoporoticvertebralfracturesandthosewithreboundassociatedvertebralfracturesfollowingdiscontinuationofdenosumab AT papapoulossocratese similaritiesanddifferencesinthemanagementofpatientswithosteoporoticvertebralfracturesandthosewithreboundassociatedvertebralfracturesfollowingdiscontinuationofdenosumab |